A double blind, double-dummy, randomised, parallel groupmulticentre trial to compare the efficacy, tolerability, endometrial and bone effects of FASLODEX (fulvestrant) 250 mg monthly with NOLVADEX (tamoxifen) 20 mg daily when given as neoadjuvant treatment in post menopausal women with primary breast cancer

Study identifier:9238IL/0042

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A double blind, double-dummy, randomised, parallel groupmulticentre trial to compare the efficacy, tolerability, endometrial and bone effects of FASLODEX (fulvestrant) 250 mg monthly with NOLVADEX (tamoxifen) 20 mg daily when given as neoadjuvant treatment in post menopausal women with primary breast cancer

Medical condition

Breast Cancer

Phase

Phase 2

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria